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Myanmar is one of 22 high tuberculosis (TB) burden coun-
tries with a high prevalence of drug-resistant Mycobacterium
tuberculosis (MTB) [1]. The Myanmar National Tuberculosis
Program uses an algorithm to screen for patients at risk of
multidrug-resistant TB (MDR-TB). Patients identified as high
risk for MDT-TB are referred to the National Tuberculosis Ref-
erence Laboratories, where phenotypic drug susceptibility
testing (DST) of the first-line anti-TB drugs isoniazid (INH),
rifampicin, ethambutol, and streptomycin is performed for
confirmation prior to enrollment in a MDR-TB treatment pro-
gram [2]. The nationwide drug-resistant TB survey conducted
in 2012–2013 identified MDR-TB among 33 (11.2%) of 295
patients in Yangon compared with 35 (4.0%) of 866 outside
Yangon. MDR-TB was confirmed among 16 (27.1%) of 58 previ-
ously treated patients [3]. Here, we report factors associated
with the occurrence of MDR-TB among previously treated
TB patients in Yangon. We collected sputum samples with
acid-fast bacilli grading 2+ or 3+ from 96 previously treated
patients that were referred to the National Tuberculosis Refer-
ence Laboratory, Yangon, between October 2012 and August
2013. Isolates were tested for MDR-TB with molecular DST
using the Hain GenoType MTBDRplus v1.0 (Hain Lifescience,
Nehren, Germany) and phenotypic DST.
Among 96 patient MTB isolates, 80 (83.3%) were MDR by
phenotypic DST. Factors associated with MDR-TB were identi-fied by logistic regression analysis (Table 1). Patients in the 19–
40 years age group were at greater risk for MDR-TB compared
with the 41–60 years age group. Patients living in East and
North Districts of Yangon Region were more likely to have
MDR-TB than those living in South District. The East and
North Districts have large urban populations depending on
factory-based employment as well as a large proportion of
migrant workers from other states and regions often living
in crowded conditions [4]. The most frequently observed
resistance mutations were the rpoB S531L (rifampicin) and
katG S315T (INH), identified in 67 (84.0%) and 77 (96.0%) of
MDR isolates, respectively, and consistent with previous stud-
ies [5,6]. One isolate had INH resistance results discrepant
between the MTBDRplus and phenotypic DST result; INH-sus-
ceptible by MTBDRplus, but INH-resistance by phenotypic
DST. We used whole-genome sequencing (WGS) to resolve
this disagreement and detected a rare mutation G299C in katG
conferring INH resistance in this isolate [7] highlighting the
added value of WGS in the diagnosis of drug-resistant TB.
Treatment after failure patients were more likely to have
MDR-TB than relapse patients, suggesting that construction
of effective regimens is needed to successfully treat drug-
resistant TB patients. Given that WGS can identify known
resistance mutations to most TB drugs, it can be used to guide
personalized treatment of drug-resistant TB patients [8,9]. In
addition, sequencing costs are declining rapidly and fullytago, Post
Table 1 – Association between factors and occurrence of multidrug-resistant tuberculosis (MDR-TB), Yangon, Myanmar, 2012–
2013.
Variable Antimicrobial resistance pattern Bivariate results
MDR N (%) Non-MDR N (%) OR (95% CI) p*
All participants 80 (83.3)/96 16 (16.7)/96 —
Sex
Male 50 (79.4)/63 13 (20.6)/63 1.0
Female 30 (90.9)/33 3 (9.1)/33 2.6 (0.68–9.87) 0.16
Age group (y)
19–40 50 (90.9)/55 5 (9.1)/55 1.0
41–60 23 (69.7)/33 10 (30.3)/33 0.23 (0.07–0.75) 0.02
61+ 7 (87.5)/8 1 (12.5)/8 0.70 (0.07–6.90) 0.76
District
South 4 (50.0)/8 4 (50.0)/8 1.0
East 33 (91.7)/36 3 (8.3)/36 11.0 (1.78–67.90) 0.01
North 23 (88.5)/26 3 (11.5)/26 7.7 (1.22–4.80) 0.03
West 20 (76.9)/26 6 (23.1)/26 3.3 (0.63–17.52) 0.16
Treatment history
Relapse 17 (73.9)/23 6 (26.1)/23 1.0
TAF 63 (91.3)/69 6 (8.7)/69 3.7 (1.06–12.96) 0.04
TAD 0 4 (100)/4 Excluded due to zero frequency
CI = confidence interval; OR = odds ratio; Relapse = a patient who was previously declared cured or treatment completed and is diagnosed with
bacteriologically-positive TB); TAD = treatment after default (a patient whose treatment was interrupted for 2 consecutive months or more);
TAF = treatment after failure (a patient previously treated for TB, who is started on a retreatment regimen after previous treatment has failed).
* p < 0.05 was considered statistically significant.
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poration of WGS into drug-resistant TB management in low-
resource settings is becoming feasible. In summary, rapid
diagnostics such as GeneXpert at township TB centers espe-
cially in North and East Districts of Yangon Region and ulti-
mately, whole-genome sequencing at the National TB
Reference Laboratory should be considered for effective diag-
nosis and treatment to reduce transmission of MDR-TB in
Yangon Region.
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